SEC Form 4
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL	

OMB Number:	
3235-0287	

Estimated average burden	

hours per response:	
0.5	

	

	

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	 	 	
1. Name and Address of Reporting Person *
Clarus Lifesciences I, L.P.	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]	5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
 	
Director	
X	
10% Owner	

 	
Officer (give title below)	
 	
Other (specify below)	

 	

 	 	
 	3. Date of Earliest Transaction (Month/Day/Year)
08/08/2012	 	 	 	
 	4. If Amendment, Date of Original Filed (Month/Day/Year)
	6. Individual or Joint/Group Filing (Check Applicable Line)
 	
Form filed by One Reporting Person	

X	
Form filed by More than One Reporting Person	

	 	 	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	 	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	 	
 	 	 	Code	V	Amount	(A) or (D)	Price	 	 	 	 	 	 	
Class A Common Stock	08/08/2012	 	C	 	7,444,168	A	$0.00(1)	8,048,433	I	By Fund (2)	 	 	 	
Class A Common Stock	08/08/2012	 	S	 	804,232	D	$11.16	7,244,201	I	By Fund (2)	 	 	 	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)	 	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	 	
 	 	 	 	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	 	 	 	 	 	 	 	 	
Series E Preferred Stock	(1)	08/08/2012	 	C	 	 	7,444,168	(1)	(1)	Class A Common Stock	7,444,168	$0.00	0	I	By Fund (2)	 	 	 	 	
1. Name and Address of Reporting Person*
Clarus Lifesciences I, L.P.	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
Clarus Ventures I Management, L.P.	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
Clarus Ventures I, LLC	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
GALAKATOS NICHOLAS	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
HENNER DENNIS	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
LIPTAK ROBERT	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
Simon Nicholas	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
STEINMETZ MICHAEL	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
1. Name and Address of Reporting Person*
WHEELER KURT	

(Last)	
(First)	
(Middle)	

C/O CLARUS VENTURES, LLC	

101 MAIN STREET, SUITE 1210	

(Street)
CAMBRIDGE	
MA	
02142	

(City)	
(State)	
(Zip)	

	
Explanation of Responses:	
1. The Company's Series E Preferred Stock automatically converted into the Company's Class A Common Stock on a one-for-one basis upon the closing of the Company's initial public offering and had no expiration date.	
2. Clarus Ventures I Management, L.P. ("Clarus I Management") as the sole general partner of Clarus Lifesciences I, L.P. (the "Fund") and Clarus Ventures I, LLC ("Clarus I GPLLC") as the sole general partner of Clarus I Management, may be deemed to beneficially own certain of the shares held of record by the Fund. Clarus I Management disclaims beneficial ownership of all shares held of record by the Fund in which Clarus I Management does not have an actual pecuniary interest. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of Clarus I GPLLC, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Clarus I GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by the Fund in which he does not have an actual pecuniary interest.	
Remarks:	
 	
 	/s/ Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P., general partner of Clarus Lifesciences I, L.P.	08/10/2012	
 	Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P.	08/10/2012	
 	Robert Liptak, Managing director of Clarus Ventures I, LLC	08/10/2012	
 	Robert Liptak, as attorney-in-fact for Nicholas Galakatos	08/10/2012	
 	Robert Liptak, as attorney-in-fact for Dennis Henner	08/10/2012	
 	Robert Liptak	08/10/2012	
 	Robert Liptak, as attorney-in-fact for Nicholas Simon	08/10/2012	
 	Robert Liptak, as attorney-in-fact for Michael Steinmetz	08/10/2012	
 	Robert Liptak, as attorney-in-fact for Kurt Wheeler	08/10/2012	
 	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below
hereby

constitutes and appoints Robert Liptak with full power to act singly, his true
and lawful

attorney-in-fact, with full power of substitution, to: (i) sign any and all
instruments,

certificates and documents that may be necessary, desirable or appropriate to be
executed on

behalf of himself as an individual or in his capacity as a general partner of
any

partnership or limited liability company, pursuant to Section 13 or 16 of the
Securities

Exchange Act of 1934, as amended, and any and all regulations promulgated
thereunder, (ii)

file the same (including any amendments thereto), with all exhibits thereto, and
any other

documents in connection therewith, with the Securities and Exchange Commission,
and any

stock exchange or similar authority and (iii) take any other action of any type
whatsoever

in connection with the foregoing which, in the opinion of such attorney-in-fact,
may be of

benefit to, in the best interest of, or legally required by, the undersigned, it
being

understood that the documents executed by such attorney-in-fact on behalf of the
undersigned

pursuant to this power of attorney shall be in such form and shall contain such
terms and

conditions as such attorney-in-fact may approve in such attorney-in-fact's
discretion,

granting unto said attorney-in-fact full power and authority to do and perform
each and

every act and thing necessary, desirable or appropriate.

Each of the undersigned hereby grant to the attorney-in-fact full power and
authority to do

and perform any and every act and thing whatsoever requisite, necessary or
proper to be done

in the exercise of any of the rights and powers herein granted, as fully to all
intents and

purposes as the undersigned might or could do if personally present with full
power of

substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact

or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause
to be done

by virtue of this power of attorney and the rights and powers herein granted.

This power of attorney shall remain in full force and effect until revoked by
the

undersigned in a signed writing delivered to the attorney-in-fact.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 11th day of
April,

2008.

/s/ Nicholas Galakatos

Nicholas Galakatos

/s/ Dennis Henner

Dennis Henner

/s/ Jeffrey Leiden

Jeffrey Leiden

/s/ Nick Simon

Nick Simon

/s/ Michael Steinmetz

Michael Steinmetz

/s/ Kurt Wheeler

Kurt Wheeler